---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018578"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:35:43.913655+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xilio reports Q3 net loss of $16.7M; cash runway into Q2 2024; XTX202 shows 50% DCR at ≥2.8 mg/kg

## Summary
- Net loss $16.7M vs $19.8M YoY; R&D spend $11.1M, G&A $6.3M.
- Cash $59.8M (Sep 30) vs $120.4M (Dec 31); runway into Q2 2024.
- XTX202 Phase 1/2: 50% disease control rate at ≥2.8 mg/kg; no vascular leak syndrome.
- XTX101: >70% tumor activation in biopsies; clinical trial collaboration with Roche to start combo with atezolizumab in Q4 2023.
- XTX301 preliminary Phase 1 safety data expected Q4 2023.

## SEC filing metadata
- accession: 0001558370-23-018578
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/0001558370-23-018578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/xlo-20231109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018578
- JSON: https://secwatch.observer/filing/0001558370-23-018578.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018578.txt

## Key facts
- Earnings Releases
  Xilio Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/0001558370-23-018578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.